Shanghai Medicilon vs Avantor: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Medicilon Inc (688202.CG)

Q3 202610 Jul – 24 Aug 2026

▲4

Medicilon swings to profit as CRO demand recovers

Medicilon turns profitable in H1 2026 Medicilon reported first-half net profit of 51.6 million yuan, reversing a year-ago loss, with revenue up 40.9% to 761 million yuan and cash flow up 80.5%. This confirms the company's own turnaround, directly supporting the stock price.
This is the single most important new fact: the company itself became profitable, validating the recovery story.
Global innovative drug R&D demand is recovering Medicilon and peer Innostar both said global demand for innovative drug research is recovering, with solid order backlogs and higher capacity use. This means more business and better pricing ahead, pushing the stock up.
It explains the underlying force behind the profit swing and is a fresh confirmation from the actual half-year reports.
Sector-wide CRO earnings surge lifts sentiment WuXi AppTec's first-half profit topped 10 billion yuan and peers like Joinn and BioMap forecast huge gains, triggering limit-up moves across CRO stocks. Medicilon rose over 13% on the coattails, as investors bet on the whole sector.
It shows the powerful sector momentum that is pulling Medicilon's stock price up alongside its own results.
Rising lab monkey prices boost CRO profits The price of cynomolgus monkeys, a key cost for some CROs, climbed to 178,000 yuan, helping drive big profit forecast increases for companies like Joinn and Medicilon. Higher prices can signal strong demand and support margins.
It is a specific new driver behind the profit upgrades that readers may not know about.

August 202610 Jul – 24 Aug 2026

▲4

Medicilon swings to profit as CRO demand recovers

Medicilon turns profitable in H1 2026 Medicilon reported first-half net profit of 51.6 million yuan, reversing a year-ago loss, with revenue up 40.9% to 761 million yuan and cash flow up 80.5%. This confirms the company's own turnaround, directly supporting the stock price.
This is the single most important new fact: the company itself became profitable, validating the recovery story.
Global innovative drug R&D demand is recovering Medicilon and peer Innostar both said global demand for innovative drug research is recovering, with solid order backlogs and higher capacity use. This means more business and better pricing ahead, pushing the stock up.
It explains the underlying force behind the profit swing and is a fresh confirmation from the actual half-year reports.
Sector-wide CRO earnings surge lifts sentiment WuXi AppTec's first-half profit topped 10 billion yuan and peers like Joinn and BioMap forecast huge gains, triggering limit-up moves across CRO stocks. Medicilon rose over 13% on the coattails, as investors bet on the whole sector.
It shows the powerful sector momentum that is pulling Medicilon's stock price up alongside its own results.
Rising lab monkey prices boost CRO profits The price of cynomolgus monkeys, a key cost for some CROs, climbed to 178,000 yuan, helping drive big profit forecast increases for companies like Joinn and Medicilon. Higher prices can signal strong demand and support margins.
It is a specific new driver behind the profit upgrades that readers may not know about.

Latest10 Jul – 24 Aug 2026

▲4

Medicilon swings to profit as CRO demand recovers

Medicilon turns profitable in H1 2026 Medicilon reported first-half net profit of 51.6 million yuan, reversing a year-ago loss, with revenue up 40.9% to 761 million yuan and cash flow up 80.5%. This confirms the company's own turnaround, directly supporting the stock price.
This is the single most important new fact: the company itself became profitable, validating the recovery story.
Global innovative drug R&D demand is recovering Medicilon and peer Innostar both said global demand for innovative drug research is recovering, with solid order backlogs and higher capacity use. This means more business and better pricing ahead, pushing the stock up.
It explains the underlying force behind the profit swing and is a fresh confirmation from the actual half-year reports.
Sector-wide CRO earnings surge lifts sentiment WuXi AppTec's first-half profit topped 10 billion yuan and peers like Joinn and BioMap forecast huge gains, triggering limit-up moves across CRO stocks. Medicilon rose over 13% on the coattails, as investors bet on the whole sector.
It shows the powerful sector momentum that is pulling Medicilon's stock price up alongside its own results.
Rising lab monkey prices boost CRO profits The price of cynomolgus monkeys, a key cost for some CROs, climbed to 178,000 yuan, helping drive big profit forecast increases for companies like Joinn and Medicilon. Higher prices can signal strong demand and support margins.
It is a specific new driver behind the profit upgrades that readers may not know about.

Avantor Inc (AVTR)

Q3 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

August 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest13 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.